Avalo Therapeutics (NASDAQ:AVTX) Stock Rating Upgraded by Wall Street Zen

Avalo Therapeutics (NASDAQ:AVTX) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other research firms also recently commented on AVTX. Guggenheim assumed coverage on shares of Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a report on Tuesday, March 24th. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. HC Wainwright increased their price target on Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Avalo Therapeutics has an average rating of “Moderate Buy” and an average price target of $42.25.

Avalo Therapeutics Stock Performance

AVTX stock opened at $13.93 on Friday. Avalo Therapeutics has a one year low of $3.39 and a one year high of $20.72. The company’s fifty day moving average price is $15.45 and its 200-day moving average price is $15.86. The company has a market capitalization of $317.46 million, a PE ratio of -2.43 and a beta of 0.84.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of ($0.21) million. On average, research analysts predict that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at $58,495.30. This trade represents a 87.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.25% of the stock is owned by company insiders.

Institutional Trading of Avalo Therapeutics

Several hedge funds have recently made changes to their positions in the business. BIT Capital GmbH purchased a new position in Avalo Therapeutics in the third quarter worth about $25,000. PFS Partners LLC raised its position in Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares during the period. Quadrature Capital Ltd purchased a new stake in Avalo Therapeutics during the second quarter valued at approximately $55,000. Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics in the 3rd quarter valued at approximately $143,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $56,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.